# Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)

> **NCT00388076** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 86 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Lapatinib
- **DRUG:** paclitaxel
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00388076
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04-28
- **Primary completion:** 2009-07-21
- **Final completion:** 2009-07-21
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2017-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00388076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00388076, "Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00388076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*